| 06-02-2009 09:13 PM CET - Health & Medicine |
|
XClinical to present End-To-End clinical process
Press release from: XClinical GmbH
(openPR) - XClinical is presenting CDISC based tools for an End-To-End clinical process
XClinical GmbH, Munich, Germany – Mai 29, 2009 – XClinical, a European vendor of innovative software products for eClinical trials, is presenting CDISC based tools for an End-To-End clinical process at the 45th DIA Annual Meeting in San Diego, USA.
At the Annual Meeting “Better Medicines: Improving Safety with Every Step“, taking place in San Diego on June 21st to June 25th 2009, the Drug Information Association is providing a meeting area for more than 8,900 professionals from over 800 exhibiting companies and more than 50 countries. 350 speaking sessions and three mega tracks are dealing with topics related to medical communications, clinical research and information technology.
In addition to XClinical’s participation as exhibitor, Dr. Claus Lindenau, Head of Business Development, is going to be speaker at the session “CDISC SDTM Data Conversion: Reusability and Repeatability”. The presentation will review the typical data transformation process to obtain CDISC SDTM and will compare advantages and disadvantages of using SAS code versus tools that use the CDISC XML based metadata. “Using tools that automatically generate mapping rules can speed up the process of validation since the generic mechanism of automatic rule generation needs to be validated only once and does not need to be completely repeated for every single trial.” Said Dr. Lindenau. “Those mechanisms help to reduce costs and to avoid time delays, which you’re facing using SAS programs to transform data from clinical trials to CDISC SDTM.”
To get an insight on the standardization of the data transformation process, attend one of XClinical’s presentations of CDISC based tools for an End-To-End clinical process at booth # 1426.
For personal appointments please contact Katharina Lang (kl@xclinical.com).
About XClinical
XClinical GmbH (www.xclinical.com), an innovative EDC-CDM system vendor based in Munich, Paris and Boston, USA, provides solutions for the electronic conduct of all types of clinical trials, post-marketing studies and registries.
XClinical develops and markets MARVIN, a CDISC ODM certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM). Till today, MARVIN was used to collect and process data of more than 50,000 patients in 70+ studies.
XClinical GmbH
Katharina Lang
Siegfriedstraße 8
80803 Munich / Germany
Phone: +49 (0)89 / 45 22 77 – 52 20
Email: press@xclinical.com
XClinical GmbH, Munich, Germany – Mai 29, 2009 – XClinical, a European vendor of innovative software products for eClinical trials, is presenting CDISC based tools for an End-To-End clinical process at the 45th DIA Annual Meeting in San Diego, USA.
At the Annual Meeting “Better Medicines: Improving Safety with Every Step“, taking place in San Diego on June 21st to June 25th 2009, the Drug Information Association is providing a meeting area for more than 8,900 professionals from over 800 exhibiting companies and more than 50 countries. 350 speaking sessions and three mega tracks are dealing with topics related to medical communications, clinical research and information technology.
In addition to XClinical’s participation as exhibitor, Dr. Claus Lindenau, Head of Business Development, is going to be speaker at the session “CDISC SDTM Data Conversion: Reusability and Repeatability”. The presentation will review the typical data transformation process to obtain CDISC SDTM and will compare advantages and disadvantages of using SAS code versus tools that use the CDISC XML based metadata. “Using tools that automatically generate mapping rules can speed up the process of validation since the generic mechanism of automatic rule generation needs to be validated only once and does not need to be completely repeated for every single trial.” Said Dr. Lindenau. “Those mechanisms help to reduce costs and to avoid time delays, which you’re facing using SAS programs to transform data from clinical trials to CDISC SDTM.”
To get an insight on the standardization of the data transformation process, attend one of XClinical’s presentations of CDISC based tools for an End-To-End clinical process at booth # 1426.
For personal appointments please contact Katharina Lang (kl@xclinical.com).
About XClinical
XClinical GmbH (www.xclinical.com), an innovative EDC-CDM system vendor based in Munich, Paris and Boston, USA, provides solutions for the electronic conduct of all types of clinical trials, post-marketing studies and registries.
XClinical develops and markets MARVIN, a CDISC ODM certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM). Till today, MARVIN was used to collect and process data of more than 50,000 patients in 70+ studies.
XClinical GmbH
Katharina Lang
Siegfriedstraße 8
80803 Munich / Germany
Phone: +49 (0)89 / 45 22 77 – 52 20
Email: press@xclinical.com
News-ID: 81836
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
XClinical GmbH
Comments about openPR
OpenPR is clearly structured and remains true to its principle of confining itself to the essential parts.
OpenPR has proven to be a very good and reliable partner to our media agency:
Within the shortest time the releases are online and go down well with the media representatives.
The success of OpenPR is reflected in the steadily increasing number of press releases.
It is good that OpenPR exists!
Ursula Koslik,Director Marketing & PR, F+W Hamburg
OpenPR has proven to be a very good and reliable partner to our media agency:
Within the shortest time the releases are online and go down well with the media representatives.
The success of OpenPR is reflected in the steadily increasing number of press releases.
It is good that OpenPR exists!
Ursula Koslik,Director Marketing & PR, F+W Hamburg


